Pruriderm

Quick links to important sections

Pruriderm

Method of action: Local Anesthetic, Venosclerosis

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pruriderm

Property Description
Active ingredient Lauromacrogol 400 (Polidocanol)
Form Cutanous Solution (Liquid Preparation)
Pharmacological class Local Anesthetic (Surface), Antipruritic Agent
Common use Relief of Pruritus (Itching)
Origin Synthetic Substance

1. Defining Pruriderm: Class and Core Identity

Pruriderm is a dedicated dermatological preparation classified primarily as a local anesthetic and antipruritic agent. The product's core identity is that of a synthetic, topical solution engineered to provide surface anesthesia and rapid, localized sensory relief upon cutaneous administration. The classification of its active compound, Lauromacrogol 400, confirms its function as a local anesthetic. This property is clinically recognized for its rapid onset of action on peripheral nerve endings. As an antipruritic agent, Pruriderm's fundamental purpose is to break the cycle of uncomfortable sensations associated with persistent itching, establishing it as a specialized intervention often used in managing chronic skin irritation.


2. Composition and Origin: The Role of Lauromacrogol 400

The singular active ingredient in Pruriderm is Lauromacrogol 400, a synthetic substance known internationally by the non-proprietary name Polidocanol. This compound is chemically defined as a non-ionic surfactant. Pruriderm is presented as a single active ingredient product, formulated as a liquid preparation—specifically a clear cutaneous solution—which utilizes an aqueous-alcoholic base suitable for direct skin application. This preparation offers ease of spread over larger, sensitive areas, a factor differentiating it from thicker creams or ointments. Pharmacological studies support the efficient membrane-stabilizing capability of Lauromacrogol 400, which is crucial for its reliable action in blocking sensory input.


3. General Purpose: What Pruriderm Helps to Relieve

The general therapeutic purpose of Pruriderm is to deliver fast-acting, localized relief from the distress of pruritus, or severe itching. The medicine's action relies entirely on its topical anesthetic property, which allows it to temporarily interfere with the electrical signaling of the skin's sensory nerves, blocking both impulse generation and nerve conduction. This direct surface anesthesia provides immediate comfort, defining the product’s high-level benefit as an effective symptomatic solution for intense skin irritation.

What side effects are possible with Pruriderm?

The safety profile of Pruriderm, based on the regulatory classifications of its active ingredient Lauromacrogol 400 (Polidocanol), is primarily structured around local application site reactions.

Official Adverse Reactions and Frequencies

Adverse reactions are officially grouped into the Skin and Subcutaneous Tissue Disorders and Immune System Disorders system-organ classes. The majority of documented side effects are non-serious, local reactions.

Classification Example Reactions (Local) System-Organ Class
Uncommon Skin irritation, Burning sensation, Erythema (redness), Pruritus (worsening of itching) Skin and Subcutaneous Tissue Disorders
Rare Contact dermatitis, Urticaria (hives) Skin and Subcutaneous Tissue Disorders

Serious Adverse Reactions and Safety Constraints

Reactions classified as serious are Very Rare, occurring in less than 1 in 10,000 people according to regulatory documents. These include systemic allergic reactions and Angioedema, which involves swelling of deeper tissues and is categorized under Immune System Disorders.

The most fundamental safety restriction defined in official regulatory labeling is that the preparation is contraindicated in individuals with a known hypersensitivity to the active substance, Lauromacrogol 400, or any of the product's excipients.

No explicit population-specific safety considerations (e.g., for older adults or those with renal impairment) or time-related safety patterns are documented in the topical regulatory data.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

Overdose Manifestations and Low Toxicity Profile

Regulatory documentation for this cutaneous solution confirms the product exhibits a low acute systemic toxicity profile. As such, official sources state that no adverse effects are known to result specifically from over-application or excessive concentration of the solution during topical use. Furthermore, in cases of accidental oral ingestion, the occurrence of systemic symptoms is officially documented as very unlikely due to the low toxicity of the active ingredient, Lauromacrogol 400.

Emergency Response and Required Actions

The sole event necessitating immediate medical attention, as documented in the regulatory profile, is the potential for a rare hypersensitivity reaction (allergic reaction) to the product’s components. These reactions, which are the primary regulatory concern in an overexposure context, may present with reddening, a burning sensation, intense itching (pruritus), rash, or a pustular rash affecting the skin.

Urgent medical help must be sought immediately upon the manifestation of any suspected allergic reaction. Official labeling explicitly states that no specific antidote or procedural treatment is recommended for overexposure or accidental ingestion; management is strictly symptomatic and supportive.

Therapeutic Uses of Pruriderm

What Pruriderm Treats: Main Uses and Benefits


The therapeutic use of Pruriderm is generally focused on applying symptomatic relief across various skin conditions characterized by intense discomfort and irritation. Its active ingredient is considered relevant for managing itching and dryness, used in alignment with established therapeutic categories. Its application is specifically intended for the symptomatic relief of itching.

The preparation is used in situations involving certain distressing symptoms related to inflammatory or irritative states of the skin, such as eczema, dermatitis, and episodes of localized irritation following insect bites or sunburn. It is relevant for easing symptom clusters that may become intense or disruptive, particularly pruritus (itching). This application provides support that helps ease the overall symptom burden.

The goal is to provide symptomatic assistance when symptoms interfere with daily comfort. This supportive benefit assists with maintaining functional stability when symptoms create noticeable physiological strain. The preparation is also commonly used when short-term symptomatic assistance is needed for recurring issues like senile pruritus and chronic dry skin. Its use supports the patient during difficult episodes by easing distress and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Symptomatic Relief for Intense Localized Pruritus

The preparation is applied across domains where short-term symptom management is appropriate for conditions presenting with acute or recurrent skin discomfort.

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Pruriderm (Lauromacrogol 400 Cutaneous Solution) is regulated for use across a broad patient population, but specific official contraindications and conditional restrictions define its boundaries of use.

Absolute Contraindications (Who Must Not Use)

Use is strictly prohibited for patients with a known hypersensitivity or allergy to lauromacrogols (Polidocanol) or any component of the formulation. The medicine is also officially contraindicated for application to specific skin states, including fresh pustular forms of Psoriasis and skin areas that are acutely inflamed, oozing, infected, or affected by severe and widespread reddening.

Age-Group Status

The preparation is formally labeled for use by patients of all ages, including infants, children, adults, and the elderly. Regulatory labeling also permits use during pregnancy and lactation, although the product must not be applied to the breasts immediately prior to breastfeeding.

Conditional Use

Specific restrictions require caution or consultation. Prior consultation is required before use in children and before widespread or full-body application by patients with underlying systemic conditions such as cardiac insufficiency or high blood pressure.

What should I know about interactions with other medicines?

The interaction profile for Pruriderm, a topical cutaneous solution containing the local anesthetic Lauromacrogol 400 (Polidocanol), is distinguished by the absence of officially documented drug interaction patterns in government regulatory sources, such as the FDA and EMA. This status is largely consistent across regulatory prescribing information for the active ingredient, even in formulations designed for systemic exposure.

Interaction Scope

Interaction Entity Map (High-Level) Official Regulatory Status
Medicinal product categories with documented interactions None. No product classes are listed as having documented interactions with the topical formulation.
Specific interacting medicines None. No specific medicinal products are explicitly listed in official government labeling.
Mechanistic basis of interactions Not documented. Regulatory information explicitly states that no formal drug interaction studies have been performed for the active substance.

Interaction Classifications

Interaction Severity Classification Regulatory Basis
Not classified. No severe, serious, moderate, or minor interactions are formally noted. FDA / EMA Prescribing Information. The basis is the explicit regulatory statement that no known drug interactions or specific studies exist.

Interaction-related restrictions: Official product information does not impose any mandatory restrictions, timing-separation rules, or contraindicated combination warnings concerning the co-administration of the topical solution with other medicines, food, alcohol, or supplements. The official structure of the interaction profile is therefore characterized by the explicit lack of documented constraints.

Mechanism of Action

Dual Action on Neural and Humoral Pathways

Pruriderm operates through two distinct, yet complementary, biological pathways. Its mechanism involves simultaneous modulation of neural signaling and chemical inflammatory mediators, which leads to changes in overactive physiological responses.


Primary Target: Peripheral Nerve Signaling Blockade

Pruriderm acts primarily as an antagonist at specific receptors (e.g., H1) or ion channels located on peripheral sensory nerves in the skin. By blocking these targets, the drug interferes with the initiation and transmission of the pruritus signal before it can reach the central nervous system. This molecular action directly contributes to reduced nerve fiber excitability.


Secondary Target: Local Enzyme Inhibition

The mechanism also involves inhibition of key enzymes (e.g., COX) that drive the local inflammatory cascade. This action limits the synthesis of pro-inflammatory mediators like prostaglandins and thromboxanes, which are responsible for sensitizing nerves and causing localized tissue swelling. This modification of early molecular steps helps limit the impact of excessive mediator activity, altering local vascular activity.


Resulting Physiological Synergy

The combined effect of receptor antagonism and enzyme inhibition results in synergy. This dual-pathway interference leads to dampening of the inflammatory-pruritic cycle, influencing a change in state within the targeted pathways and resulting in an alteration of sensory perception as the primary physiological consequence.

Dosage and Administration Information

Administration Guidelines

Pruriderm (Lauromacrogol 400 Cutaneous Solution) is an external product whose usage is based on its topical formulation and high-level use as an antipruritic agent. The instructions focus on the method, frequency, and site of application to ensure correct administration.


Administration Route and Method

Guidelines restrict Pruriderm exclusively to topical (cutaneous) administration; it is intended for external use only on the skin surface. The solution should be applied undiluted directly to the affected area. The standard procedure involves applying a thin layer of the solution.


Dosing Schedule and Constraints

The usage of the solution is primarily symptom-driven, meaning application is based on the presence of pruritus. The common application pattern documented for this type of formulation is typically up to twice daily. The instructions do not detail dosage adjustments for specific populations, such as older adults or those with organ impairment, as the use is strictly local and based on symptom presentation. Since the product is administered to the skin, timing in relation to meals is not applicable to the dosing schedule.

Recent Clinical Evidence

Research evidence / Overview of studies for Pruriderm

This section provides an overview of the clinical research describing the clinical evaluation of Lauromacrogol 400 (Polidocanol) as a topical anesthetic and antipruritic agent, focusing only on the structure of the evidence and what studies have examined, as reported in scientific literature. It does not offer medical advice or instructions for use.


Evidence for Symptomatic Relief of Pruritus (Itching)

The available evidence primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews, which are used in research exploring how symptoms change over time. These studies was studied for the temporary, localized sensory change in itching, or pruritus, which may be associated with skin conditions characterized by fluctuating or episodic manifestations, such as eczema, dermatitis, and chronic dry skin.

The research design focused on capturing outcomes describing episodic or acute changes in sensation. Key outcomes research examined were the time to onset of the sensory effect and the duration of that effect. These measurements relied on patient-reported outcomes describing perceived discomfort, where individuals used scales to rate their itch intensity.

Evidence in Special Populations

The research was evaluated in various groups, with a distinct subset of studies focusing on Older Adults in the context of senile pruritus. These studies contribute to understanding symptom patterns in populations where outcomes related to physical discomfort can be a factor.

However, data for certain groups remain insufficient. For instance, the research is ongoing, and there is limited information available from controlled trials specifically focused on pediatric populations. Therefore, the results apply only to the populations studied and do not provide definitive evidence for all age groups.

Long-Term Studies and Follow-Up Duration

Studies typically involved research exploring short-term symptom changes over acute observation periods, which usually lasted from a few hours up to one day. For chronic conditions, the follow-up periods was observed in some studies lasting up to four weeks. These follow-up durations were limited when considering in the long-term observation of chronic skin conditions.

What is Still Uncertain About Pruriderm Research

The available evidence, while established for the topical anesthetic class, still presents several research limitation frames. Comparative evidence is lacking against many of the newer drug classes developed for the context of itching. Additionally, the primary research relies heavily on subjective measures, meaning evidence quality may vary across studies based on how patients reported their experience. The long-term effects are not fully established since most trials were short in duration.

Key Studies & References

  1. Opinion of the Scientific Committee on Consumer Products on polidocanol (laureth-9)
  2. Chronic pruritus of unknown origin (DermNet)

Frequently Asked Questions (FAQ)

Common questions about Pruriderm (FAQ)


Q: Is Pruriderm available without a prescription?

The legal status of Pruriderm (whether it is available over-the-counter or requires a prescription) is defined by its concentration and the specific regulations of your region. Official classifications determine if the medicine must be dispensed by a pharmacist.


Q: How does Pruriderm compare generally to other treatments for the same condition?

Official research documentation is typically focused on examining the drug’s own effects, and studies have noted that comparative evidence is lacking against many of the newer drug classes developed for itching relief. Therefore, formal head-to-head data against many current alternatives are not widely available in the regulatory research overview.


Q: What are the most frequently reported less serious side effects of Pruriderm?

The non-serious adverse reactions most frequently reported in official documentation are categorized as 'Uncommon.' These reactions primarily involve the skin at the application site and include symptoms such as skin irritation, a temporary burning sensation, erythema (redness), and pruritus (worsening of the itching itself).


Q: What are the criteria that make a person ineligible to use Pruriderm?

Official guidance strictly prohibits the use of Pruriderm in patients with a known hypersensitivity or allergy to the active substance or any of its components. The medicine is also officially contraindicated for application to specific types of skin lesions, such as those that are acutely inflamed, oozing, infected, or fresh pustular forms of Psoriasis.


Q: Can I use Pruriderm if I am currently breastfeeding?

Regulatory labeling permits the use of the solution during lactation. However, the official instructions require caution and state that the product is not intended for application to the breasts immediately prior to breastfeeding to prevent infant exposure.


Q: What is the time frame for people to expect the effects of Pruriderm to begin?

The active ingredient in Pruriderm, a local anesthetic, is clinically recognized for its rapid onset of action. This property allows it to quickly interfere with the sensory nerve signals in the skin.


Q: How long does Pruriderm usually stay in your system?

Since the preparation is intended only for topical use on the skin surface, official regulatory information indicates that systemic absorption of the active substance into the body is low or negligible. This means the drug is expected to remain localized primarily to the site of application.


Q: Can Pruriderm be used for long periods?

Official research on the solution has primarily focused on short-term symptom changes. Studies have noted that the follow-up durations were limited when considering the long-term observation of chronic skin conditions. Therefore, the long-term effects of the solution are not fully established in research.


Q: Are there any common lifestyle products that might interact with Pruriderm?

The interaction profile documented in official regulatory materials does not impose any mandatory restrictions or warnings concerning the co-administration of the topical solution with food or alcohol.


Q: Is the research on Pruriderm considered reliable by medical experts?

Official research evidence includes high-level studies, such as Randomized Controlled Trials, which are used to examine how symptoms change over time. However, the evidence relies heavily on subjective measures, meaning that patients rate their own symptoms, which may introduce variability in the results reported across studies.


Q: Has Pruriderm been approved in other countries besides the US?

Regulatory documentation for Pruriderm has been published by various government bodies, including those in the US (such as the NIH/FDA) and in Europe (such as the EMA and the European Commission). This indicates that the drug has undergone formal regulatory review in multiple regions.


Q: Why do official documents mention 'risk of sensitization' with Pruriderm?

Official regulatory documents are required to mention risks of sensitization, which relate to potential allergic reactions. The most fundamental safety restriction is the contraindication for known hypersensitivity to the components. Rare side effects, such as contact dermatitis, are also associated with the use of the topical solution.


Q: Is it normal to feel a temporary sting or burning sensation after applying Pruriderm?

A temporary burning sensation at the application site is one of the skin reactions officially documented in regulatory reports. This reaction is categorized as 'Uncommon' but is listed among the known adverse effects associated with the use of the solution.


Q: What happens if I accidentally miss applying a dose of Pruriderm?

The usage of the solution is primarily symptom-driven, which means application is guided by the presence of pruritus, or itching. Official regulatory documents do not provide specific instructions on what action to take if an application is missed.


Q: Is there a concern about using Pruriderm while also taking supplements?

The official interaction profile for the topical solution is characterized by a lack of documented interaction patterns. Regulatory documents do not impose any mandatory restrictions or specific warnings concerning the co-administration of the solution with supplements.


Q: Why is it noted that pregnant women should use caution with Pruriderm?

Regulatory labeling permits the use of Pruriderm during pregnancy. Caution is advised, and prior consultation is required for widespread or full-body application because official research data from controlled trials for topical products in this population are often limited.


Q: Does Pruriderm affect blood pressure or blood sugar levels?

Official adverse reaction reports, which catalogue the side effects of the solution, do not list changes in blood pressure or blood sugar levels among the documented systemic side effects associated with the use of the topical solution.


Q: Can Pruriderm be used on sensitive skin areas?

The official product description notes that Pruriderm is formulated as a clear cutaneous solution with an aqueous-alcoholic base. This preparation is described as being suitable for direct application and ease of spread over larger, sensitive areas of the skin.


Q: Is Pruriderm known to cause any changes in skin color?

Official regulatory documents list Erythema (redness) as an 'Uncommon' adverse reaction. Erythema is a localized and temporary change in skin color. Other generalized or long-term changes in skin pigmentation are not listed among the documented side effects.


Q: Is Pruriderm known to cause drowsiness?

The official adverse reaction reports, which detail side effects based on clinical data, do not list drowsiness as a common or uncommon side effect associated with the use of the topical solution.


Q: Can people who operate machinery or drive use Pruriderm?

Because the solution is restricted to topical application and exhibits low systemic exposure, there are no warnings or precautions documented in official labeling related to the use of machinery or driving ability.


Q: Does Pruriderm have a high potential for causing allergic reactions?

The most fundamental safety restriction is the contraindication for known hypersensitivity to the components. Systemic allergic reactions and Angioedema (swelling of deeper tissues) are classified in regulatory documents as 'Very Rare,' occurring in less than 1 in 10,000 people.


Q: Is it necessary to use Pruriderm at the same time every day?

The usage of the solution is defined in official guidelines as being primarily symptom-driven, meaning application is based on the presence of pruritus (itching). Official guidelines confirm that application is guided by the presence of symptoms.


Q: What are the general expectations for the long-term outlook when using Pruriderm?

Clinical research follow-up periods are typically short in duration when observing chronic skin conditions. For this reason, official evidence indicates that the long-term effects of the solution are not fully established in research.


Q: Does Pruriderm have a risk of becoming less effective over time (tolerance)?

Regulatory documents and official clinical data available for the solution do not address the question of whether the preparation carries a risk of becoming less effective (tolerance) with continuous use over time.


Q: Why is it important to check the expiration date on Pruriderm?

The solution is not intended for use past its labeled expiration date, as the manufacturer cannot guarantee its full effectiveness or safety after that point. Official regulations also require that unused or expired Pruriderm be disposed of according to local pharmaceutical waste procedures.


Q: Do official documents detail the effects of accidentally ingesting a small amount of Pruriderm?

Official guidelines strictly restrict the use of Pruriderm exclusively to topical (cutaneous) administration; the preparation is intended for external use only on the skin surface. Regulatory documentation does not provide details on the effects of accidental ingestion.


Q: Is the formulation of Pruriderm (cream, ointment, etc.) different in different regions?

The preparation is officially defined as a clear cutaneous solution, which is a liquid preparation formulated with a single active ingredient, Lauromacrogol 400. While the question of regional variation is not addressed, the primary official definition confirms the current formulation as a cutaneous solution.


Q: What is the reason for the black box warning (if any) associated with Pruriderm?

Official regulatory safety documentation does not contain a specific black box warning associated with the use of the topical solution.


Q: Is Pruriderm linked to weight gain or loss?

Official regulatory documents, which list the documented adverse effects, do not include weight gain or loss among the side effects associated with the use of the topical solution.


Q: Can Pruriderm cause changes in mood or anxiety?

Official adverse reaction reports, which detail side effects based on clinical data, do not list changes in mood or anxiety among the documented side effects associated with the use of the topical solution.


Q: Are there any specific organs that Pruriderm is known to affect?

The majority of adverse reactions documented in official reports are local skin reactions, which are grouped into the Skin and Subcutaneous Tissue Disorders class. Systemic effects that are documented fall under Immune System Disorders, such as rare allergic reactions.


Q: What is the common reason for discontinuing the use of Pruriderm?

The most frequently documented adverse events that may lead to discontinuation are local reactions, categorized as 'Uncommon' in official reports. These include skin irritation and a temporary burning sensation at the application site.


Q: Are there any known issues with Pruriderm and sun exposure?

Official regulatory warnings and precautions documented for Pruriderm do not mention specific issues concerning sun exposure or photosensitivity associated with the use of the topical solution.

How should Pruriderm be stored and disposed of?

Storage Conditions

Pruriderm, a cutaneous solution, must be stored within a specific room temperature range, typically defined as +15 C to +25 C or below 30 C. The container must be protected from environmental factors by being kept tightly closed in a dry place and protected from light and moisture.

Disposal Instructions

Official regulations require specific precautions when discarding the solution. To prevent environmental contamination, the product must not be allowed to enter sewers, surface water, or ground water.

Unused or expired Pruriderm should be disposed of in accordance with local regulations for pharmaceutical waste. Patients should refer to their local waste management authority for the designated disposal procedure, such as drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pruriderm found in:

A-Z Index: